11 ESMO24 presentations published on NEJM

“ESMO24 Round Up: 11 articles were simultaneously published in NEJM and presented at this year’s ESMO Congress in Barcelona, Spain. Most of the articles included a podcast with NEJM Group editors discussing the significance of the trial results.”

The articles presented at ESMO24 are the following:

Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

Authors: Ying Cheng, David R. Spigel, Byoung Chul Cho, Konstantin K. Laktionov, Jian Fang, Yuanbin Chen, Yoshitaka Zenke, Ki Hyeong Lee, Qiming Wang, Alejandro Navarro, Reyes Bernabe, Eva Lotte Buchmeier, John Wen-Cheng Chang, Yoshimasa Shiraishi, Sema Sezgin Goksu, Andrzej Badzio, Anhui Shi, Davey B. Daniel, Nguyen Thi Thai Hoa, Milada Zemanova, Helen Mann, Hema Gowda, Haiyi Jiang, Suresh Senan, for the ADRIATIC Investigators

Pembrolizumab in HER2-Positive Gastric Cancer (KEYNOTE-811)|Article

NEJM at ESMO — Pembrolizumab in HER2+ Gastric Cancer|Podcast

Authors: Yelena Y. Janjigian, Akihito Kawazoe, Yuxian Bai, Jianming Xu, Sara Lonardi, Jean Phillipe Metges, Patricio Yañez, Lucjan S. Wyrwicz, Lin Shen, Yuriy Ostapenko, Mehmet Bilici, Hyun Cheol Chung, Kohei Shitara, Shukui Qin, Eric Van Cutsem, Josep Tabernero, Suxia Luo, Mauricio Mahave, Yong Tang, Maeve Lowery, Maria M.F. Monteiro, Linzhi Xu, Chie-Schin Shih, Kanu P. Sharan, Pooja Bhagia, Sun Young Rha

Preoperative Chemoradiotherapy for Resectable Gastric Cancer (TOPGEAR)|Article

NEJM at ESMO – Preoperative Chemoradiotherapy for Resectable Gastric Cancer|Podcast

Authors: Trevor Leong, Mark Smithers, Michael Michael, Karin Haustermans, Rebecca Wong, Val Gebski, Rachel L. O’Connell, John Zalcberg, Alex Boussioutas, Michael Findlay,David Willis, Alisha Moore, William K. Murray, Florian Lordick, Chris O’Callaghan, Carol Swallow, Gail Darling, Danielle Miller, Andrew Strickland, Moishe Liberman, Laurent Mineur, John Simes,

Ponsegromab for the Treatment of Cancer Cachexia|Article

NEJM at ESMO — Ponsegromab in Cancer Cachexia|Podcast

Authors: John D. Groarke, Jeffrey Crawford, Susie M. Collins, Shannon Lubaczewski, Eric J. Roeland, Tateaki Naito, Andrew E. Hendifar, Marie Fallon, Koichi Takayama, Timothy Asmis, Richard F. Dunne, Isik Karahanoglu, Carrie A. Northcott, Magdalena A. Harrington, Michelle Rossulek,  Ruolun Qiu, Aditi R. Saxena

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) | Article

NEJM at ESMO — Adjuvant Pembrolizumab versusObservation in Muscle-Invasive Urothelial Carcinoma | Podcast

Authors: Andrea B. Apolo, Karla V. Ballman, Guru Sonpavde, Stephanie Berg, William Y. Kim, Rahul Parikh, Min Yuen Teo, Randy F. Sweis, Daniel M. Geynisman, Petros Grivas, Gurkamal Chatta, Zachery Roger Reichert, Joseph W. Kim, Mehmet Asim Bilen, Bradley McGregor, Parminder Singh, Abhishek Tripathi, Suzanne Cole, Nicholas Simon, Scot Niglio, Lisa Ley, Lisa Cordes, Sandy Srinivas, Jiaoti Huang, Meagan Odegaard, Colleen Watt, Daniel Petrylak, Jeannie Hoffman-Censits, Yujia Wen, Olwen Hahn, Cecilia Mitchell, Alan Tan, Howard Streicher, Elad Sharon, Helen Moon, Michael Woods, Susan Halabi, Gabriela Perez Burbano, Michael J. Morris, Jonathan E. Rosenberg,

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer (DESTINY-Breast06) | Article 

NEJM at ESMO — Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer | Podcast

Authors: Aditya Bardia, Xichun Hu, Rebecca Dent, Kan Yonemori, Carlos H. Barrios, Joyce A. O’Shaughnessy, Hans Wildiers, Jean-Yves Pierga, Qingyuan Zhang, Cristina Saura, Laura Biganzoli, Joohyuk Sohn, Seock-Ah Im, Christelle Lévy, William Jacot, Natasha Begbie, Jun Ke, Gargi Patel, B.Chir., Giuseppe Curigliano,

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma (CheckMate 067)|Article

NEJM at ESMO — Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma|Podcast

Authors: Jedd D. Wolchok, Vanna Chiarion-Sileni, Piotr Rutkowski, C. Lance Cowey, Dirk Schadendorf, John Wagstaff, Paola Queirolo, Reinhard Dummer, Marcus O. Butler, Andrew G. Hill, Michael A. Postow, Caroline Gaudy-Marqueste, Theresa Medina, Christopher D. Lao,  John Walker, Iván Márquez-Rodas, John B.A.G. Haanen, Massimo Guidoboni, Michele Maio, Patrick Schöffski, Matteo S. Carlino, Shahneen Sandhu, Céleste Lebbé, Paolo A. Ascierto, Georgina V. Long, Corey Ritchings, Ayman Nassar, Margarita Askelson, Melanie Pe Benito, Wenjia Wang, F. Stephen Hodi, James Larkin,

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer (NIAGARA)|Article

NEJM at ESMO — Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer|Podcast

Authors: Thomas Powles, James W.F. Catto, Matthew D. Galsky, Hikmat Al-Ahmadie, Joshua J. Meeks, Hiroyuki Nishiyama, Toan Quang Vu, Lorenzo Antonuzzo, Pawel Wiechno, Vagif Atduev, Ariel G. Kann, Tae-Hwan Kim, Cristina Suárez, Chao-Hsiang Chang, Florian Roghmann, Mustafa Özgüroğlu, Bernhard J. Eigl, Niara Oliveira, Tomas Buchler, Moran Gadot, Yousef Zakharia, Jon Armstrong, Ashok Gupta, Stephan Hois, Michiel S. van der Heijden,

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (KEYNOTE-522)|Article

NEJM at ESMO — Overall Survival with Pembrolizumab in Early-Stage Triple- Negative Breast Cancer|Podcast

Authors: Peter Schmid, Javier Cortes, Rebecca Dent, Heather McArthur, Lajos Pusztai, Sherko Kümmel, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Seock-Ah Im, Michael Untch, Peter A. Fasching, Marie-Ange Mouret-Reynier, Theodoros Foukakis, Marta Ferreira, Fatima Cardoso, Xuan Zhou, Vassiliki Karantza, Konstantinos Tryfonidis, Gursel Aktan, Joyce O’Shaughnessy,

Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma|Article

NEJM at ESMO — Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma|Podcast

Authors: Kohei Shitara, Manish A Shah, Florian Lordick, Eric Van Cutsem, David H Ilson, Samuel J Klempner, Yoon-Koo Kang, Sara Lonardi, Yi-Ping Hung, Kensei Yamaguchi, Peter Enzinger, Tomoko Nakajima, Maria Matsangou, Ying Cao, Ran Li, Diarmuid Moran, Rupesh Pophale, Mok Oh, Radhika Ranganath, Jaffer A Ajani, Rui-Hua Xu

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors|Article

NEJM at ESMO — Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine Tumors|Podcast

Authors: Jennifer A. Chan, Susan Geyer, Tyler Zemla,  Michael V. Knopp,  Spencer Behr, Sydney Pulsipher, Fang-Shu Ou, Amylou C. Dueck, Jared Acoba, Ardaman Shergill, Edward M. Wolin,  Thorvardur R. Halfdanarson, Bhavana Konda, Nikolaos A. Trikalinos, Bernard Tawfik, Nitya Raj,  Shagufta Shaheen, Namrata Vijayvergia, Arvind Dasari, Jonathan R. Strosberg, Elise C. Kohn, Matthew H. Kulke, Eileen M. O’Reilly, Jeffrey A. Meyerhardt,

Individuals shared a post by NEJM, adding:

Paolo Tarantino:

“Impressive to see 11 ESMO24 presentations concomitantly published on NEJM! Each accompanied by a dedicated podcast episode Though I would have loved to see a written editorial for DB06.”

Andres Cervantes:

“I am thankful to NEJM for promoting the science presented at ESMO Congress in Barcelona.”

Giampaolo Bianchini:

“Terrific achievement by ESMO!! A stellar quality demonstrated by the astonishing number of simultaneous publications in outstanding journals! Congrats to Rebecca D Sin, Andres Cervantes, Karin Jordan, the Scentific Track Chairs and the members of the Scientific Committees.”

More posts featuring ESMO24 on oncodaily.com

Best of ESMO24